Smart Cancer Nanomedicine for Synergetic Therapy

Title:Smart Cancer Nanomedicine for Synergetic Therapy

Volume: 31

Author(s): Anwesha Kanungo, Chandana Mohanty and Sarbari Acharya*

Affiliation:

• School of Applied Sciences, Kalinga Institute of Industrial Technology, Bhubaneswar, 751024, Odisha, India

Abstract: Cancer is the second leading cause of death. Notwithstanding endeavors to comprehend tumor causes and therapeutic modalities, no noteworthy advancements in cancer therapy have been identified. Nanomedicine has drawn interest for its diagnostic potential because of its ability to deliver therapeutic agents specifically to tumors with little adverse effects. Nanomedicines have become prevalent in the treatment of cancer. Here, we present four strategic suggestions for improvement in the functionality and use of nanomedicine. (1) Smart drug selection is a prerequisite for both medicinal and commercial achievement. Allocating resources to the advancement of modular (pro)drugs and nanocarrier design ought to consider the role of opportunistic decisions depending on drug availability. (2) Stimuli-responsive nanomedicine for cancer therapy is being designed to release medications at particular locations precisely. (3) The cornerstone of clinical cancer treatment is combination therapy. Nanomedicines should be included more frequently in multimodal combination therapy regimens since they complement pharmacological and physical co-treatments. (4) Regulation by the immune system is transforming cancer therapy. Nanomedicines can improve the effectiveness of the immune system and control the behavior of anticancer immunity. These four approaches, both separately and particularly in combination, will accelerate and promote the creation of effective cancer nanomedicine treatments.

Cite this article as:

Kanungo Anwesha, Mohanty Chandana and Acharya Sarbari*, Smart Cancer Nanomedicine for Synergetic Therapy, Current Medicinal Chemistry 2024; 31 () . https://dx.doi.org/10.2174/0109298673300897240602130258